Edition:
United States

Onxeo SA (C4X.PA)

C4X.PA on Paris Stock Exchange

1.05EUR
21 Sep 2018
Change (% chg)

€-0.02 (-2.14%)
Prev Close
€1.08
Open
€1.07
Day's High
€1.09
Day's Low
€1.05
Volume
83,520
Avg. Vol
147,301
52-wk High
€2.49
52-wk Low
€0.98

Chart for

About

Onxeo SA, formerly Bioalliance Pharma SA, is a France-based biopharmaceutical company. In July 2014, the Company, as the continuing entity, merged with Topotarget AS creating Onxeo, a company dedicated to orphan oncology diseases. Onxeo aims at holding a portfolio of advanced programs targeting severe pathologies with unmet... (more)
No analyst recommendations are available for .

Overall

Beta: 0.85
Market Cap(Mil.): €53.66
Shares Outstanding(Mil.): 50.91
Dividend: --
Yield (%): --

Financials

  C4X.PA Industry Sector
P/E (TTM): -- 30.48 32.69
EPS (TTM): -1.11 -- --
ROI: -67.50 13.04 12.72
ROE: -80.94 14.99 14.85

BRIEF-Onxeo Announces Start Of DRIIV Phase 1 Clinical Study Of AsiDNA

* ANNOUNCES START OF DRIIV, PHASE 1 CLINICAL STUDY OF ASIDNA IN ADVANCED SOLID TUMORS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Apr 24 2018

BRIEF-Onxeo FY Recurring Operating Loss Narrows To EUR 19.2‍​ Million

* FY REVENUE EUR ‍​9.5 MILLION VERSUS EUR 4.4 MILLION YEAR AGO

Mar 29 2018

Earnings vs. Estimates